In this video, we unpack how cell therapy is shifting from a niche intervention to a platform technology that is reshaping the broader cell and gene therapy landscape. We show how CAR‑T and emerging approaches such as TCR‑T, CAR‑NK, TILs and in‑vivo CAR‑T are moving into new indications, earlier lines of therapy, and allogeneic “off‑the‑shelf” formats.

The deck also highlights what is driving and constraining this transition: biological hurdles in solid tumors, complex manufacturing, rising but selective investor interest, evolving pricing and reimbursement models, and fast‑moving regulatory frameworks in the US and EU. Overall, the message is that scientific innovation is no longer the only differentiator; companies that master scale, access, and execution will shape the next phase of growth in cell therapy.